Literature DB >> 35212958

NLRP3 Phospho-residue Mapping by Phospho Dot Blots.

Sangeetha Shankar1, Zsofia A Bittner1, Alexander N R Weber2.   

Abstract

When characterizing posttranslational modifications like phosphorylation, using efficient screening methods to map the phospho sites is essential, especially when dealing with large multi-domain proteins. NLRP3 (the NOD, LRR, and pyrin domain-containing protein 3), which initiates the formation of an NLRP3 inflammasome complex, is regulated posttranslationally by phosphorylation at several Ser and Tyr residues. However, determining sites of modification are not straightforward. For quick and reliable screening of the candidate phospho sites in NLRP3, we use a phospho dot blot assay which we describe here. This technique employs an in vitro kinase assay with a candidate kinase, Bruton's Tyrosine Kinase (BTK), and peptides derived from the region of interest in the protein that contains the potential phosphorylation sites. The reaction containing the phosphorylated peptides is quickly screened by a dot blot where the peptides are blotted with a commercially available anti-phospho-tyrosine antibody. This method can also be adapted to detect modified Ser or Thr residues and is an ideal screening assay to map phospho residues in NLRP3 or other proteins. This can be an initial screening procedure or can be complemented by other approaches such as site directed mutagenesis and by generating phospho site-specific antibodies.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BTK; Dot blot; NLRP3; NLRP3 inflammasome; Phosphorylation; Posttranslational modification; Tyrosine phosphorylation

Mesh:

Substances:

Year:  2022        PMID: 35212958     DOI: 10.1007/978-1-0716-2144-8_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.

Authors:  Xiao Liu; Tica Pichulik; Olaf-Oliver Wolz; Truong-Minh Dang; Andrea Stutz; Carly Dillen; Magno Delmiro Garcia; Helene Kraus; Sabine Dickhöfer; Ellen Daiber; Lisa Münzenmayer; Silke Wahl; Nikolaus Rieber; Jasmin Kümmerle-Deschner; Amir Yazdi; Mirita Franz-Wachtel; Boris Macek; Markus Radsak; Sebastian Vogel; Berit Schulte; Juliane Sarah Walz; Dominik Hartl; Eicke Latz; Stephan Stilgenbauer; Bodo Grimbacher; Lloyd Miller; Cornelia Brunner; Christiane Wolz; Alexander N R Weber
Journal:  J Allergy Clin Immunol       Date:  2017-02-16       Impact factor: 10.793

2.  A dot-immunobinding assay for monoclonal and other antibodies.

Authors:  R Hawkes; E Niday; J Gordon
Journal:  Anal Biochem       Date:  1982-01-01       Impact factor: 3.365

Review 3.  Targeting the NLRP3 inflammasome in inflammatory diseases.

Authors:  Matthew S J Mangan; Edward J Olhava; William R Roush; H Martin Seidel; Gary D Glick; Eicke Latz
Journal:  Nat Rev Drug Discov       Date:  2018-07-20       Impact factor: 84.694

4.  A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses.

Authors:  Annick Mayor; Fabio Martinon; Thibaut De Smedt; Virginie Pétrilli; Jürg Tschopp
Journal:  Nat Immunol       Date:  2007-04-15       Impact factor: 25.606

5.  Protein kinase D at the Golgi controls NLRP3 inflammasome activation.

Authors:  Zhirong Zhang; Gergö Meszaros; Wan-Ting He; Yanfang Xu; Helena de Fatima Magliarelli; Laurent Mailly; Michael Mihlan; Yansheng Liu; Marta Puig Gámez; Alexander Goginashvili; Adrien Pasquier; Olga Bielska; Bénédicte Neven; Pierre Quartier; Rudolf Aebersold; Thomas F Baumert; Philippe Georgel; Jiahuai Han; Romeo Ricci
Journal:  J Exp Med       Date:  2017-07-17       Impact factor: 17.579

6.  Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis.

Authors:  Marianne R Spalinger; Marlene Schwarzfischer; Larissa Hering; Ali Shawki; Anica Sayoc; Alina Santos; Claudia Gottier; Silvia Lang; Katharina Bäbler; Annelies Geirnaert; Christophe Lacroix; Gabriel E Leventhal; Xuezhi Dai; David Rawlings; Andrew A Chan; Gerhard Rogler; Declan F McCole; Michael Scharl
Journal:  Mucosal Immunol       Date:  2019-09-09       Impact factor: 7.313

7.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

Authors:  Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.